• The University of Western Australia (M519), 35 Stirling Highway,

    6009 Perth


  • 892 Citations
  • 12 h-Index
If you made any changes in Pure these will be visible here soon.

Personal profile


After 19 years of research in molecular pharmacology, I still feel a sense of wonder at the workings of the tiny things that make up the cells of our bodies. My research aims to make better medicines that are more effective and have fewer side effects.

Since graduating from UWA, I have worked at the UWA Centre for Medical Research and Harry Perkins Institute of Medical Research studying G protein-coupled receptors (GPCRs).  I am a co-inventor of assay technology and have worked on academic and commercial projects.

My experience working at the academic-industry interface led to my current secondment as Senior Project Officer with Accelerating Australia; a consortium providing training and support for researchers at the early stage of commercialisation, focussed on Medical Technology and Pharmacology.

Education/Academic qualification

Human Biology, B. Sc. (Hons)


External positions

Senior Project Officer, Accelerating Australia

Feb 2018 → …


  • Medicine and Pharma
  • Drug Discovery
  • Molecular pharmacology
  • G protein-coupled receptors (GPCR)
  • Protein interactions
  • Bioluminescence resonance energy transfer (BRET)
  • Assay technology
  • Arrestin
  • Heteromerisation
  • Endocrinology—receptors

Fingerprint Dive into the research topics where Ruth Seeber is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles
Energy Transfer Medicine & Life Sciences
Bioluminescence Chemical Compounds
Arrestin Chemical Compounds
Thyrotropin Releasing Hormone Receptors Medicine & Life Sciences
Energy transfer Chemical Compounds
G-Protein-Coupled Receptors Medicine & Life Sciences
CXC Chemokines Medicine & Life Sciences
Arrestins Chemical Compounds

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2002 2019

  • 892 Citations
  • 12 h-Index
  • 18 Article
  • 3 Conference paper
  • 2 Patent
  • 1 Poster
4 Citations (Scopus)

Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis

Pickering, R., Tikellis, C., Rosado, C., Tsorotes, D., Dimitrropoulos, A., Smith, M., Huet, O., Seeber, R., Abhayawardana, R., Johnstone, E., Golledge, J., Wang, Y., Jandeleit-Dahm, K., Cooper, M., Pfleger, K. & Thomas, M. C., 2 Jan 2019, In : The Journal of clinical investigation. 129, 1, p. 406-421 CI99987.

Research output: Contribution to journalArticle

Open Access
Transcriptional Activation
Angiotensin II

Experiential Training Courses for Medical Technology and Pharmaceutical Translation

Seeber, R. & Pfleger, K., 28 Nov 2018.

Research output: Contribution to conferencePoster

Pharmaceutical Technology
Biomedical Research
Organized Financing
11 Citations (Scopus)

Mutations of vasopressin receptor 2 including novel L312S have differential effects on trafficking

Tiulpakov, A., White, C., Abhayawardana, R., See, H. B., Chan, A., Seeber, R., Heng, J., Dedov, I., Pavlos, N. & Pfleger, K., 1 Aug 2016, In : Molecular Endocrinology. 30, 8, p. 889-904

Research output: Contribution to journalArticle

Open Access
Vasopressin Receptors
Nephrogenic Diabetes Insipidus
12 Citations (Scopus)

Molecular determinants of orexin receptor-arrestin-ubiquitin complex formation

Jaeger, W., Seeber, R., Eidne, K. & Pfleger, K., Jan 2014, In : British Journal of Pharmacology. 171, 2, p. 364-374

Research output: Contribution to journalArticle

Open Access
20 Citations (Scopus)

Characterization of Three Vasopressin Receptor 2 Variants: An Apparent Polymorphism (V266A) and Two Loss-of-Function Mutations (R181C and M311V)

Armstrong, S., Seeber, R., Ayoub, M., Feldman, B. J. & Pfleger, K., 2013, In : PLoS One. 8, 6, p. 9pp e65885.

Research output: Contribution to journalArticle

Open Access

Projects 2013 2014